Influence of Diagnosis Timing and Therapeutic Regimens of Allergic Rhinitis on Pregnancy Outcomes in Pregnant Patients
Background and Objective Allergic rhinitis (AR) is a common allergic comorbidity in pregnant women. However, the correlation between AR onset/intervention timing and pregnancy outcomes remains insufficiently supported by large-sample evidence, and no unified standard has been established for the clinical application of different therapeutic regimens. This study aimed to investigate the influence of AR diagnosis timing and different therapeutic regimens on pregnancy outcomes in pregnant patients with AR, thereby providing evidence-based references for the standardized diagnosis and treatment of gestational AR. Methods This multicenter retrospective cohort study enrolled 5,083 pregnant patients with AR from two clinical centers: the Harvard University Partners Healthcare System (PARTNERS), and Longgang District Maternity & Child Healthcare Hospital of Shenzhen City in China. All participants completed full pregnancy follow-up between January 2016 and December 2024. The baseline data, AR diagnosis timing, therapeutic regimens and pregnancy outcome-related indicators of the patients were collected. The correlations of AR diagnosis timing (pre-pregnancy vs. intra-pregnancy) and four therapeutic regimens (intranasal corticosteroids, oral antihistamines, combination therapy, and no treatment) with pregnancy outcomes were analyzed. Results A total of 80.1% of patients were diagnosed with AR before pregnancy. The vaginal delivery rate in the pre-pregnancy diagnosis group was significantly higher than that in the intra-pregnancy diagnosis group (90.6% vs. 71.7%, P < 0.001), while the rates of cesarean section (9.4% vs. 28.3%, P < 0.001), low birth weight (4.0% vs. 6.9%, P = 0.002), neonatal complications (36.3% vs. 44.1%, P < 0.001), and abnormal 1-minute (7.7% vs. 16.3%, P < 0.001) and 5-minute Apgar scores < 7 (0.8% vs. 4.7%, P < 0.001) were significantly lower. No significant difference was observed in the preterm birth rate between the two groups (10.4% vs. 11.6%, P = 0.18). Significant differences in pregnancy outcomes were also found among therapeutic regimens (P < 0.05). Notably, the combination therapy group showed an unusually high vaginal delivery rate (98.2%) and elevated low birth weight rate (9.3%), which warrant careful data verification. Conclusion Pre-pregnancy diagnosis and standardized intervention for AR are associated with improved maternal and infant prognosis and reduced risk of adverse pregnancy outcomes. Treatment of gestational AR should follow the principle of individualization, with regimens selected based on patients' high-risk factors. Given the univariable nature of the regression analysis, these findings should be interpreted as observational associations rather than independent effects, and prospective studies with confounder adjustment are needed for confirmation.
Authors
- Jie Zhou (ORCID: https://orcid.org/0000-0003-3031-3895)
- Yao Yao (ORCID: https://orcid.org/0000-0001-9604-5358)
- Qiuling Shi
- Fang Li
- Yousha Wang
- Tingyu Luo
- Lingling Xiong
- Cheng Lei
- Zhiling Zeng
- Jinsong Li
- Fan Li
Institutions
- Chongqing Normal University (CN)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- University of Electronic Science and Technology of China (CN)
- Chongqing University (CN)
- Shenzhen Maternity and Child Healthcare Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Chongqing Public Health Medical Center (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11410674/v1
- Primary Topic
- Pregnancy and Medication Impact
- Type
- preprint